✦ LIBER ✦

STAC: A phase II study of carboplatin/paclitaxel/bevacizumab followed by randomization to either bevacizumab alone or erlotinib and bevacizumab in the upfront management of patients with ovarian, fallopian tube or peritoneal cancer

✍ Scribed by S. Campos; T. Atkinson; S. Berlin; M. Roche; C. Whalen; U. Matulonis; N. Horowitz; M. Birrer; R. Penson

Book ID: 113962911
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 48 KB
Volume: 120
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2010.12.188

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PointBreak: A Randomized Phase III Study

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer

✍ Patel, J. D.; Socinski, M. A.; Garon, E. B.; Reynolds, C. H.; Spigel, D. R.; Ols 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 243 KB

A phase II clinical trial of pegylated l

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

✍ Marcela G. del Carmen; John Micha; Laurie Small; Daron G. Street; Anil Londhe; T 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 254 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

✍ Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Ho 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 100 KB

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Late-Breaking Abstract 5: Results from a

Late-Breaking Abstract 5: Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

✍ C. Aghajanian; S. Blank; B. Goff; P. Judson; L. Nycum; M. Sovak; J. Yi; A. Husai 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB

A phase I study with an expanded cohort

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Natalie Gould; Michael W. Sill; Robert S. Mannel; P.H. Thaker; Paul DiSilvestro; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 162 KB